125 related articles for article (PubMed ID: 30016731)
1. Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
Leung AWY; Anantha M; Dragowska WH; Wehbe M; Bally MB
J Control Release; 2018 Sep; 286():1-9. PubMed ID: 30016731
[TBL] [Abstract][Full Text] [Related]
2. DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.
Leung AWY; Chen KTJ; Ryan GM; Anantha M; Wretham N; Nosrati Z; Heroux D; Wang L; Chow N; Dai Z; Bally MB
J Control Release; 2022 May; 345():75-90. PubMed ID: 35259461
[TBL] [Abstract][Full Text] [Related]
3. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
[TBL] [Abstract][Full Text] [Related]
4. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
5. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
6. Development of a copper-clioquinol formulation suitable for intravenous use.
Wehbe M; Malhotra AK; Anantha M; Lo C; Dragowska WH; Dos Santos N; Bally MB
Drug Deliv Transl Res; 2018 Feb; 8(1):239-251. PubMed ID: 29247315
[TBL] [Abstract][Full Text] [Related]
7. Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.
Mathuber M; Hager S; Keppler BK; Heffeter P; Kowol CR
Dalton Trans; 2021 Nov; 50(44):16053-16066. PubMed ID: 34617075
[TBL] [Abstract][Full Text] [Related]
8. Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development.
Wehbe M; Anantha M; Backstrom I; Leung A; Chen K; Malhotra A; Edwards K; Bally MB
PLoS One; 2016; 11(4):e0153416. PubMed ID: 27055237
[TBL] [Abstract][Full Text] [Related]
9. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
10. The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
Yan S; Frank D; Son J; Hannan KM; Hannan RD; Chan KT; Pearson RB; Sanij E
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117679
[TBL] [Abstract][Full Text] [Related]
11. CX-5461 inhibits RNA Pol I in blood cancers.
Cancer Discov; 2014 Dec; 4(12):OF5. PubMed ID: 25477122
[TBL] [Abstract][Full Text] [Related]
12. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
[TBL] [Abstract][Full Text] [Related]
13. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy.
Duo Y; Yang M; Du Z; Feng C; Xing C; Wu Y; Xie Z; Zhang F; Huang L; Zeng X; Chen H
Acta Biomater; 2018 Oct; 79():317-330. PubMed ID: 30172068
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.
Chen KTJ; Militao GGC; Anantha M; Witzigmann D; Leung AWY; Bally MB
J Control Release; 2021 May; 333():246-257. PubMed ID: 33798663
[TBL] [Abstract][Full Text] [Related]
15. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
16. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
17. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
18. Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.
Prosser KE; Leung AWY; Harrypersad S; Lewis AR; Bally MB; Walsby CJ
Chemistry; 2018 Apr; 24(24):6334-6338. PubMed ID: 29490115
[TBL] [Abstract][Full Text] [Related]
19. Nanoformulations of a potent copper-based aquaporin inhibitor with cytotoxic effect against cancer cells.
Nave M; Castro RE; Rodrigues CM; Casini A; Soveral G; Gaspar MM
Nanomedicine (Lond); 2016 Jul; 11(14):1817-30. PubMed ID: 27388811
[TBL] [Abstract][Full Text] [Related]
20. Copper(i) complexes with phosphine derived from sparfloxacin. Part III: multifaceted cell death and preliminary study of liposomal formulation of selected copper(i) complexes.
Kyzioł A; Cierniak A; Gubernator J; Markowski A; Jeżowska-Bojczuk M; Komarnicka UK
Dalton Trans; 2018 Feb; 47(6):1981-1992. PubMed ID: 29345262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
